New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
07:03 EDTENDP, BDSIBioDelivery Sciences announces Buprenorphine study to be locked by Endo Health
The database for the BEMA Buprenorphine Phase 3 clinical study in opioid naive patients with chronic pain is expected to be locked shortly by BDSI's partner, Endo Pharmaceuticals. This event is expected to trigger a $10M milestone payment from Endo per the licensing and development agreement signed in January 2012. In addition, based on recruitment rates in a second Phase 3 clinical study of BEMA Buprenorphine in an opioid experienced patient group, the database for this trial is anticipated to be locked by mid-2014, with results following shortly thereafter.
News For BDSI;ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
05:53 EDTBDSIBioDelivery Sciences assumed with an Overweight at Piper Jaffray
Subscribe for More Information
April 16, 2015
07:03 EDTENDPEndo price target raised to $110 from $102 at Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use